Previous close | 549.12 |
Open | 553.89 |
Bid | 399.98 x 1100 |
Ask | 547.05 x 800 |
Day's range | 542.32 - 556.32 |
52-week range | 462.61 - 832.70 |
Volume | |
Avg. volume | 173,056 |
Market cap | 16.144B |
Beta (5Y monthly) | 0.95 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.39 |
Earnings date | 26 Oct 2022 - 31 Oct 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 700.00 |
HERCULES, Calif., August 03, 2022--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (WSE NewConnect: SCP), a Warsaw, Poland, based developer of innovative technology solutions for the medical diagnostic and healthcare markets, for a total consideration of up to $170 mil
Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.
Bio-Rad (BIO) delivered earnings and revenue surprises of 37.40% and 3.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?